FATE
Fate Therapeutics Inc
2.10$
-0.9%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.1% | +0.0% | -0.1% | +0.0% | +0.1% | -0.1% | +0.1% | -0.1% | +61.9% | +58.5% | +7.0% | -13.8% | +15.4% | -10.2% | +117.3% | +38.3% | +110.3% | -29.9% | +20.4% | +6.1% | +20.0% | +7.9% | +0.7% | -19.2% | +196.1% | +33.0% | -98.4% | +108.4% | -13.8% | +14.9% | +251.8% | -54.6% | -39.5% | -12.4% | +17.1% | -8.7% | -21.4% | -5.1% | +60.3% | – | |
| – | -8.4% | +27.9% | -0.5% | +8.2% | +15.3% | +16.1% | +46.5% | -18.9% | +3.4% | +25.8% | +22.0% | +7.3% | +8.7% | +16.1% | -8.9% | +15.1% | +27.0% | +15.1% | +7.1% | +10.6% | +30.8% | +3.8% | +12.7% | -1.8% | +9.2% | -24.7% | -37.7% | -88.4% | +3.1% | -1.3% | -2.1% | +634.0% | -50.5% | +70.0% | -86.9% | +576.2% | -88.1% | -4.7% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1,055.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1,639.5% | – | – | – | – | – | -218.3% | – | – | |
| – | -8.4% | +27.9% | -0.5% | +8.2% | +15.3% | +16.1% | +46.5% | -18.9% | +3.4% | +25.8% | +22.0% | +7.3% | +8.7% | +16.1% | -8.9% | +15.1% | +27.0% | +15.1% | +7.1% | +10.6% | +30.8% | +3.8% | +12.7% | -1.8% | +9.2% | -24.7% | -37.7% | -16.1% | -7.2% | +1.0% | +7.7% | +0.1% | -3.0% | -13.3% | -5.9% | -5.8% | -1.6% | -14.3% | +11.9% | – | |
| – | -6.1% | +23.7% | -12.0% | +4.5% | +21.4% | +6.5% | +5.9% | +6.9% | +5.5% | +24.2% | -1.5% | +20.4% | +5.1% | +15.9% | -2.9% | +11.3% | +23.5% | +21.2% | -2.7% | +29.2% | +7.7% | +22.5% | -1.9% | +5.9% | +0.1% | +1.7% | +3.1% | -16.2% | -5.3% | +16.3% | -17.3% | +20.6% | -26.6% | -9.8% | -16.9% | -7.1% | +0.3% | -10.0% | -8.0% | – | |
| – | -7.8% | +26.7% | -3.7% | +7.3% | +16.8% | +13.6% | +36.8% | -14.1% | +3.9% | +25.4% | +16.6% | +9.8% | +7.9% | -75.8% | -2.9% | +11.3% | +23.5% | +21.2% | -2.7% | +29.2% | +7.7% | +22.5% | -1.9% | +5.9% | +0.1% | +1.7% | +3.1% | +114.3% | -7.5% | +7.4% | -2.2% | -55.9% | +123.4% | -70.4% | +154.5% | -69.7% | +239.3% | -13.0% | +5.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -14.5% | -19.1% | -20.3% | +78.3% | +9.0% | +0.0% | +3.2% | +0.9% | +0.2% | -5.8% | +1.0% | -2.2% | +34.5% | +80.7% | -34.7% | -29.6% | -22.6% | +9.0% | -8.2% | -16.5% | +2.8% | +40.7% | +81.1% | +136.1% | +61.2% | +237.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -532.4% | – | +23.4% | +175.9% | -134.7% | – | +13.6% | -9.8% | +141.0% | +33.5% | -7.0% | -10.3% | -24.1% | – | – | – | – | – | – | -235.4% | – | – | – | – | – | – | – | – | – | -74.6% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.